Share on StockTwits

Omnicell (NASDAQ:OMCL) Director James T. Judson sold 5,000 shares of Omnicell stock on the open market in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $29.28, for a total transaction of $146,400.00. Following the completion of the transaction, the director now directly owns 23,894 shares in the company, valued at approximately $699,616. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Omnicell (NASDAQ:OMCL) traded up 1.09% on Thursday, hitting $29.72. 93,521 shares of the company’s stock traded hands. Omnicell has a 52 week low of $19.37 and a 52 week high of $30.33. The stock’s 50-day moving average is $27.02 and its 200-day moving average is $27.02. The company has a market cap of $1.088 billion and a P/E ratio of 39.84.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, May 1st. The company reported $0.26 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.24 by $0.02. The company had revenue of $101.80 million for the quarter, compared to the consensus estimate of $97.49 million. During the same quarter in the prior year, the company posted $0.21 earnings per share. The company’s quarterly revenue was up 16.9% on a year-over-year basis. On average, analysts predict that Omnicell will post $1.23 earnings per share for the current fiscal year.

A number of research firms have recently commented on OMCL. Analysts at Topeka Capital Markets initiated coverage on shares of Omnicell in a research note on Thursday, June 12th. They set a “buy” rating and a $30.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Omnicell in a research note on Thursday, May 29th. They now have a $28.00 price target on the stock. Finally, analysts at Stephens initiated coverage on shares of Omnicell in a research note on Tuesday, May 20th. They set an “overweight” rating on the stock. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $30.71.

Omnicell, Inc (NASDAQ:OMCL) is a provider of automated solutions for hospital medication and supply management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.